PABRON 50

- ◆PABRON 50 TABLETS is a cold medication that contains western-style active ingredients (acetaminophen and potassium guaiacolsulfonate) to relieve cold symptoms such as throat pain and chills. It also contains the crude ingredient "bakumondoto extract" to moisten the throat membrane and induce excretion of sputum.
- ◆The product does not contain any ingredients that induce drowsiness or dry mouth, or cause difficult urination (antihistaminics), ingredients that may cause constipation (dihydrocodeine phosphate), or ingredients that affect diabetes and hypertension (dl-Methylephedrine hydrochloride).

Indication

To alleviate cold symptoms (sore throat, chill, fever, headache, joint pain, muscle pain, and sputum)

Dosage and administration

Take the following dose with cold or lukewarm water within 30 minutes after a meal whenever possible.

15 years or over: 4 tablets per dose, 3 times daily

Under 15 years: Do not take

Precaution

- · Comply with the prescribed dosage and administration instructions.
- Do not return the tablets touched by wet fingers into the jar. (It will cause discoloration and may deteriorate the quality)

Ingredient

In 4 tablets

Acetaminophen 150mg

Potassium Guaiacolsulfonate 80mg

Bakumondoto extract dry extract 600mg

(Dried extracts of the following crude drugs)

(Bakumondoto 533.3mg (1600mg per 12 tablets), Glycyrrhiza 133.3mg (400mg per 12 tablets), Nonglutinous rice 666.7mg (2000mg per 12 tablets), Jujube 200mg (600mg per 12 tablets), Ginseng 133.3mg (400mg per 12 tablets), Pinelliae tuber 333.3mg (1000mg per 12 tablets))

Excipients

Anhydrous silicic acid, aluminum silicate, carboxymethylcellulose calcium, magnesium stearate, corn starch

Precaution

The drug contains herbal medicine as a raw ingredient. The color of the drug may differ slightly, but this will not affect the efficacy.

Precautions

When not to use the product

(If you do not follow these instructions, the current symptoms may worsen or adverse reactions are more likely to occur)

- This product should not be taken in the following persons
 - Patients who have had an allergic symptom to this drug or its ingredients.

Patients who have experienced asthma from taking this drug or other cold remedies, antipyretic analgesics.

- This drug should not be taken together with the following drugs
 - Other cold medicines, antipyretics/analgesics, sedatives, expectorants
- Do not drink alcohol before and after taking this drug
- Do not take this medicine for a long time

Consultation

• The following persons should contact a physician, pharmacist, or registered salesperson for a consultation before administration

Patients undergoing medical treatment from a physician or dentist.

Pregnant women or women suspected of being pregnant.

Patients who have experienced allergic symptoms associated with drugs, etc.

Persons with the following symptoms.

23 March 2022 1 / 2page

Hyperthermia

Persons diagnosed as having the following.

Heart disease, liver disease, kidney disease, gastric/duodenal ulcer

• If the following symptoms are observed after taking this drug, these may be adverse reactions, so immediately discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation

Skin: rash/redness, itching

Gastrointestinal system: nausea and vomiting, loss of appetite

Neuropsychiatric system: dizziness Other: excessive temperature decrease

• Serious symptoms listed on the right column may occur in rare cases. In such cases, immediately consult your physician.

Shock (anaphylaxis): symptoms, such as itching of skin, urticaria, hoarseness, sneezing, itchy throat, breathing difficulties, palpitations, and clouding of consciousness may occur immediately after take.

Oculomucocutaneous syndrome (stevens-johnson syndrome), toxic epidermal necrolysis, acute generalised exanthematous pustulosis: hyperthermia, ocular hyperaemia, eye discharge, lip erosion, pain throat, widespread skin rash/redness, small pimples (small pustules) on reddened skin, general malaise, anorexia, etc. may persist or suddenly worsen.

Hepatic function failure: symptoms, such as fever, itching, rash, jaundice (yellowing of skin and white of eyes), brown urine, general malaise, loss of appetite, etc. may occur.

Kidney disorders: symptoms, such as fever, rash, reduced urinary volume, general oedema, general malaise, arthralgia (painful joints) and diarrhea, etc. may occur.

Interstitial pneumonia: shortness and/or difficulties of breath when go upstairs or overwork, sudden dry cough and/or fever and its continuance.

Asthma: symptoms, such as wheezing or hissing when breathing, and difficult breathing, etc. may occur.

• When symptoms do not improve even after taking the medicine 5 to 6 times, stop taking this medicine and consult a physician, pharmacist or registered salesperson, being sure to take this instruction leaflet with you

Precautions for storage and handling

- Store in a cool, low humidity place away from direct sunlight.
- · Store the product beyond the reach of children.
- Do not transfer the drug to other containers. (It may lead to misuse or quality deterioration)
- Do not take the product past the expiration date. Even within the expiration date, try to take it up as soon as possible once it is opened. (to assure the quality)

(Disclaimer on Multilingual Product Information)

- •This product is a pharmaceutical product approved under a Japanese law, the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices, with a view to its sale and use in Japan.
- •Multilingual product information is a translation of the product labeling written in Japanese and provided for your information only. It does not warrant that its contents and the product itself conforms to laws and regulations in countries other than Japan.
- •Multilingual product information is a tentative translation by the provider (or Our Company), and may be modified or altered without notice.
- •The provider (or Our Company) assumes no responsibility for any occurred problem attributable to the contents of the multilingual product information.

23 March 2022 2 / 2page

21